These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35181735)

  • 1. Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module.
    Lee HK; Knabl L; Knabl L; Wieser M; Mur A; Zabernigg A; Schumacher J; Kapferer S; Kaiser N; Furth PA; Hennighausen L
    Sci Rep; 2022 Feb; 12(1):2784. PubMed ID: 35181735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation.
    Lee HK; Knabl L; Knabl L; Wieser M; Mur A; Zabernigg A; Schumacher J; Kaiser N; Furth PA; Hennighausen L
    medRxiv; 2021 May; ():. PubMed ID: 34100027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.
    Widera M; Wilhelm A; Hoehl S; Pallas C; Kohmer N; Wolf T; Rabenau HF; Corman VM; Drosten C; Vehreschild MJGT; Goetsch U; Gottschalk R; Ciesek S
    J Infect Dis; 2021 Oct; 224(7):1109-1114. PubMed ID: 34223909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
    Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
    Front Immunol; 2021; 12():730766. PubMed ID: 34630410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host genetic variants associated with COVID-19 reconsidered in a Slovak cohort.
    Skerenova M; Cibulka M; Dankova Z; Holubekova V; Kolkova Z; Lucansky V; Dvorska D; Kapinova A; Krivosova M; Petras M; Baranovicova E; Baranova I; Novakova E; Liptak P; Banovcin P; Bobcakova A; Rosolanka R; Janickova M; Stanclova A; Gaspar L; Caprnda M; Prosecky R; Labudova M; Gabbasov Z; Rodrigo L; Kruzliak P; Lasabova Z; Matakova T; Halasova E
    Adv Med Sci; 2024 Mar; 69(1):198-207. PubMed ID: 38555007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence of Protein S Variant in Patients Diagnosed with COVID-19.
    Bayirli-Turan D; Usanmaz M; Gorgun S; Yolcu E; Sahin C; Bilenoglu O; Isbilen M; Yildiz E
    Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.
    Nonaka CKV; Franco MM; Gräf T; de Lorenzo Barcia CA; de Ávila Mendonça RN; de Sousa KAF; Neiva LMC; Fosenca V; Mendes AVA; de Aguiar RS; Giovanetti M; de Freitas Souza BS
    Emerg Infect Dis; 2021 May; 27(5):1522-1524. PubMed ID: 33605869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
    Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
    Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant.
    Knabl L; Lee HK; Wieser M; Mur A; Zabernigg A; Knabl L; Rauch S; Bock M; Schumacher J; Kaiser N; Furth PA; Hennighausen L
    medRxiv; 2021 May; ():. PubMed ID: 34013280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of BNT162b First Vaccination on the Immune Transcriptome of Elderly Patients Infected with the B.1.351 SARS-CoV-2 Variant.
    Knabl L; Lee HK; Wieser M; Mur A; Zabemigg A; Knabl L; Rauch S; Bock M; Schumacher J; Kaiser N; Furth P; Hennighausen L
    Res Sq; 2021 Jun; ():. PubMed ID: 34100009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of SARS-CoV-2 mutations at the early stage of the pandemic in Istanbul population.
    Uyar Y; Mart Kömürcü SZ; Artik Y; Cesur NP; Tanrıverdi A; Şanlı K
    Ann Clin Microbiol Antimicrob; 2024 Oct; 23(1):93. PubMed ID: 39390548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance.
    Anisul M; Shilts J; Schwartzentruber J; Hayhurst J; Buniello A; Shaikho Elhaj Mohammed E; Zheng J; Holmes M; Ochoa D; Carmona M; Maranville J; Gaunt TR; Emilsson V; Gudnason V; McDonagh EM; Wright GJ; Ghoussaini M; Dunham I
    Elife; 2021 Aug; 10():. PubMed ID: 34402426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.
    Sabin AP; Richmond CS; Kenny PA
    Diagn Microbiol Infect Dis; 2022 May; 103(1):115656. PubMed ID: 35231807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A discernable increase in the severe acute respiratory syndrome coronavirus 2 R.1 lineage carrying an E484K spike protein mutation in Japan.
    Sekizuka T; Itokawa K; Hashino M; Okubo K; Ohnishi A; Goto K; Tsukagoshi H; Ehara H; Nomoto R; Ohnishi M; Kuroda M; ;
    Infect Genet Evol; 2021 Oct; 94():105013. PubMed ID: 34352360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern.
    Liang Y; Lin H; Zou L; Zhao J; Li B; Wang H; Lu J; Sun J; Yang X; Deng X; Tang S
    Microbiol Spectr; 2021 Dec; 9(3):e0101721. PubMed ID: 34787487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.